Annual Report 2018
Abacus Medicine delivers on ambitious growth targets
2018 was another year of high, organic growth. Revenue rose by 31% to EUR 332.3 million in 2018 against EUR 253.1 million the previous year, according to the Group’s annual report for 2018, published today.
Adjusted EBITDA rose even more – by 39% to EUR 13.6 million against EUR 9.8 million in 2017. Profit for the year 2018 of EUR 5.4 million was the highest result ever for the company.
“We delivered on ambitious financial targets once again. A remarkable team performance in itself, but we did more than that. What marks 2018 as an exceptional year for Abacus Medicine was that we simultaneously carried out several large development projects to lay the foundation for the company’s future growth,“ said CEO and founder Flemming Wagner.
View the full Abacus Medicine Annual Report 2018
We are happy to help, so please get in touch. Below you will find our main offices, but we have people covering all of Europe.
1620 Copenhagen V
Maglódi út 6
Berliner Straße 8
The Leadenhall Building,
122 Leadenhall Street,
London EC3V 4AB
12/14 Rond-Point des Champs-Elysées
Paris 75008, France
I am text block. Click edit button to change this text.